CATALOGO DEI PRODOTTI DELLA RICERCA

QUAGLIA, Francesca Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.956
EU - Europa 3.322
AS - Asia 2.325
SA - Sud America 274
AF - Africa 202
Continente sconosciuto - Info sul continente non disponibili 146
OC - Oceania 20
Totale 10.245
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.646
RU - Federazione Russa 1.680
SG - Singapore 879
IT - Italia 846
BD - Bangladesh 327
VN - Vietnam 315
CN - Cina 311
GB - Regno Unito 187
BR - Brasile 182
HK - Hong Kong 172
CA - Canada 154
DE - Germania 115
BJ - Benin 87
FR - Francia 86
IN - India 86
NL - Olanda 59
SE - Svezia 56
MX - Messico 53
ES - Italia 49
IE - Irlanda 48
PL - Polonia 38
NG - Nigeria 37
FI - Finlandia 34
JP - Giappone 34
ID - Indonesia 32
AR - Argentina 29
AT - Austria 24
KR - Corea 22
TR - Turchia 22
ZA - Sudafrica 21
CR - Costa Rica 19
TN - Tunisia 19
AU - Australia 17
EC - Ecuador 17
HN - Honduras 17
PH - Filippine 17
CO - Colombia 14
IL - Israele 13
RO - Romania 13
IQ - Iraq 12
GT - Guatemala 11
PT - Portogallo 11
SA - Arabia Saudita 11
VE - Venezuela 11
JM - Giamaica 10
PK - Pakistan 10
TT - Trinidad e Tobago 10
UA - Ucraina 10
CH - Svizzera 9
EG - Egitto 9
NI - Nicaragua 9
BE - Belgio 8
BG - Bulgaria 8
CW - ???statistics.table.value.countryCode.CW??? 8
SV - El Salvador 8
TH - Thailandia 8
CL - Cile 7
LT - Lituania 7
PR - Porto Rico 7
AE - Emirati Arabi Uniti 6
GR - Grecia 6
MY - Malesia 6
PS - Palestinian Territory 6
QA - Qatar 6
SC - Seychelles 6
ET - Etiopia 5
IR - Iran 5
PY - Paraguay 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
HR - Croazia 4
PE - Perù 4
TG - Togo 4
TW - Taiwan 4
LB - Libano 3
MA - Marocco 3
OM - Oman 3
UZ - Uzbekistan 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CG - Congo 2
DZ - Algeria 2
GE - Georgia 2
GP - Guadalupe 2
KE - Kenya 2
KZ - Kazakistan 2
MD - Moldavia 2
MT - Malta 2
NO - Norvegia 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
TZ - Tanzania 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
Totale 10.089
Salva come PNG Salva come JPEG
Città #
Moscow 716
San Jose 648
Ashburn 601
Singapore 522
Verona 232
Council Bluffs 223
Dallas 205
Hong Kong 166
New York 143
Los Angeles 110
Ho Chi Minh City 99
Chandler 96
Cotonou 87
Milan 78
Beijing 74
Hanoi 73
Santa Clara 60
Buffalo 56
Orem 49
Rome 47
Dublin 44
Montreal 40
Bologna 39
London 39
McKinney 37
Phoenix 37
The Dalles 37
Warsaw 33
Houston 32
São Paulo 32
Atlanta 30
Toronto 29
Mexico City 28
Chennai 27
Tokyo 26
Brooklyn 24
Naples 24
Denver 23
Xi'an 23
Munich 21
Stockholm 21
Frankfurt am Main 20
Abuja 19
Jacksonville 19
Annandale 18
Chicago 18
Haiphong 18
Helsinki 18
Lagos 18
Seattle 18
Da Nang 17
Poplar 17
Cleveland 16
Manchester 16
San José 16
Johannesburg 15
Jakarta 14
North Hollywood 14
Querétaro 14
Southend 14
Mumbai 13
Philadelphia 13
Amsterdam 12
Turin 12
Boston 11
Bucharest 11
Falkenstein 11
Madrid 11
Melbourne 11
North Bergen 11
Padua 11
Princeton 11
Vancouver 11
Wilmington 11
Bari 10
Boardman 10
Charlotte 10
Columbus 10
Guatemala City 10
Lawrence 10
Lisbon 10
Stuttgart 10
Venice 10
Washington 10
Florence 9
Tianjin 9
Vienna 9
Ankara 8
Belfast 8
City of London 8
Dong Ket 8
Hyderabad 8
Jinan 8
Lappeenranta 8
Managua 8
Miami 8
Palermo 8
Redondo Beach 8
Willemstad 8
Bogotá 7
Totale 5.640
Salva come PNG Salva come JPEG
Nome #
T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: CLINICO-PATHOLOGICAL FEATURES AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS 411
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 250
The rs1001179 SNP and CpG methylation regulate catalase expression in chronic lymphocytic leukemia 223
Chronic lymphocytic leukemia and mantle cell lymphoma: similarities and differences from an integrated biological and clinical approach 217
Fentanyl buccal tablet: a new breakthrough pain medication in early management of severe vaso-occlusive crisis in sickle cell disease. 211
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 196
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 189
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 188
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study 186
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 177
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group 172
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 171
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 165
Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease 162
Differential diagnosis of lymphocytosis in routine laboratory practice: the contribution of Sysmex- XN9100 159
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 151
Bendamustine plus rituximab: is it a BRIGHT idea? 149
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 142
GENOMIC ANALYSES OF PATIENTS WITH MANTLE CELL LYMPHOMA THAT WERE REFRACTORY OR RELAPSED AFTER INDUCTION THERAPY: RESULTS FROM THE FIL_MANTLE- FIRST BIO STUDY 140
SCOPING OUT CARDIOVASCULAR ASSESSMENT ON INITIATION AND SUBSEQUENT MONITORING DURING BTKI THERAPY, AN ERIC INITIATIVE 132
CATALASE BLOCKING INDUCES APOPTOSIS AND POTENTIATES VENETOCLAX-INDUCED CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 131
CAT RS1001179 SINGLE NUCLEOTIDE POLYMORPHISM IDENTIFIES AN AGGRESSIVE CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA 126
Different infiltration patterns within the tumor microenvironment can identify mantle cell lymphoma patients with different clinical outcomes. Results from a pilot clinical-pathological study 120
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 113
Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin's Lymphoma: A Case Report and Review of the Literature 110
IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY 109
A phospho-specific flow cytometry study reveals the impact of BCR signaling activation in mantle cell lymphoma progression and therapy 106
THE PROGNOSTIC ROLE OF DEL 9P21.3 (CDKN2A) IN PATIENTS WITH MANTLE CELL LYMPHOMA. RESULTS FROM THE FIL_MANTLE-FIRST BIO STUDY 105
BCR signaling activity stratifies patents with MCL with divergent clinical outcome 105
THE ROLE OF STEM CELL TRANSPLANTATION AS CONSOLIDATION THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 104
PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF THE B-CELL RECEPTOR SIGNALING IN MANTLE CELL LYMPHOMA 103
B-CELL RECEPTOR SIGNALING ACTIVITY IDENTIFIES PATIENTS WITH MANTLE CELL LYMPHOMA AT HIGHER RISK OF PROGRESSION 103
ACTIVATION OF BCR SIGNALING REWIRES THE RESPONSE OF BCR-ASSOCIATED KINASES TO IBRUTINIB IN MANTLE CELL LYMPHOMA CELLS 98
IN CHRONIC LYMPHOCYTIC LEUKAEMIA WITH COMPLEX KARYOTYPE, MAJOR STRUCTURAL ABNORMALITIES IDENTI- FY A SUBSET OF PATIENTS WITH INFERIOR OUTCOME AND DISTINCT BIOLOGIC CHARACTERISTICS 98
THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 95
R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy 94
FITNESS STATUS AND TIME TO FIRST PROGRESSION IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE “ELDERLY MANTLE-FIRST” STUDY 91
ARGO, AUTOMATIC RECORD GENERATOR IN ONCOLOGY: MULTICENTRIC VALIDATION OF A NEW TOOL FOR AUTO- MATIC CONVERSION OF “REAL-LIFE” HEMOLYMPHOPATHOL- OGY REPORTS IN STANDARDIZED ECRF 90
Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation 88
Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs 87
DIFFERENT MICROENVIRONMENTAL PATTERNS OF T-CELL INFILTRATION CAN IDENTIFY MANTLE CELL LYMPHOMA PATIENTS WITH DISTINCT CLINICAL OUTCOMES. RESULTS FROM A PILOT CLINICAL-PATHOLOGICAL STUDY 85
An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920) 85
GENETIC AND EPIGENETIC MECHANISMS REGULATING CATALASE EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA 85
B-CELL RECEPTOR SIGNALING PROFILES IDENTIFY SUBSETS OF MANTLE CELL LYMPHOMA PATIENTS WITH DIFFERENT CLINICAL OUTCOMES 83
THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 82
A REAL-LIFE STUDY OF DARATUMUMAB-BORTEZOMIB-DEX- AMETHASONE (DVD) IN LENALIDOMIDE EXPOSED/REFRAC- TORY MULTIPLE MYELOMA PATIENTS: A REPORT FROM THE MYELOMA TRIVENETO WORKING GROUP 82
Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study 81
OUTCOME OF 100 TP53-DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED FRONT-LINE WITH IBRUTINIB. A REAL-LIFE CAMPUS CLL STUDY. 80
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study 78
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations 77
B-CELL RECEPTOR SIGNALING PROFILES IN MANTLE CELL LYMPHOMA: A BARCODING AND PHOSPHO-SPECIFIC FLOW CYTOMETRY APPROACH 75
Association of genetic polymorphisms with differential catalase gene expression in prognostic groups of chronic lymphocytic leukemia patients. 74
A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY 74
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL) 73
A MULTI‐CENTER REAL‐LIFE ANALYSIS ON PATIENTS WITH LARGE B‐CELL LYMPHOMA AFTER FAILURE OF CAR‐T CELLS THERAPY 73
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 71
Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. 71
Worldwide Examination of Patients with CLL Hospitalized for COVID-19 71
THE PROGNOSTIC SIGNIFICANCE OF MYC AND BCL2 PROTEIN DOUBLE EXPRESSION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, NOS, IN THE ABSENCE OF MYC REARRANGEMENT 70
OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYM- PHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY 68
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 67
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report 66
A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY 66
RESPONSE TO IBRUTINIB OF AN AGGRESSIVE IG-A LYMPHOPLASMACYTIC LYMPHOMA CARRYING THE MYD88 L265P GENE MUTATION 65
IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL‐LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY 65
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 63
CATALASE EXPRESSION IN LEUKEMIA CELLS IS CONTROLLED BY GENETIC AND EPIGENETIC MECHANISMS 63
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.” 60
Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus 60
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study 59
Callosal agenesis in craniofrontonasal dysplasia 59
Paraaortic PEComa 59
HBV REACTIVATION IN CLL PATIENTS WITH OCCULT HBV INFECTION TREATED WITH IBRUTINIB WITH OR WITHOUT VIRAL PROPHYLAXIS. A RETROSPECTIVE MULTICENTRIC GIMEMA STUDY 59
Fluorescent cell barcoding and phospho-specific flow cytometry characterize B-cell receptor signaling profiles associated with different clinical outcome in mantle cell lymphoma 59
VALIDATION OF AN INFECTION RISK SYSTEM IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH THE IDELALISIB-RITUXIMAB REGIMEN 58
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL) 57
AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS OF OUTCOME AND CHEMOREFRACTORINESS 57
Atherosclerotic ectasia of coronary arteries 57
Recurrent infiltrative cancer of the cheek: a case report 56
Diagnosis of groove pancreatitis in patient with chronic pancreatitis and recurrent abdominal pain 55
Simultaneous abdominal histoplasmosis and cerebral toxoplasmosis in an AIDS patient 55
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 54
Regulation of catalase gene expression in chronic lymphocytic leukemia patients. 54
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: results from the ELDERLY MANTLE-FIRST study 54
Left main coronary artery aneurysm 53
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 52
Brachial aneurysm following arterovenous fistula ligation 52
Cavernous sinus thrombosis: exophtalmos in a patient with Internal Carotid Artery (ICA) aneurysm 51
Notch signaling is a poor prognostic factor in Acute Myeloid Leukemia (AML). 51
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 50
Gastroepiploic artery bypass graft 49
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 49
Subacute combined degeneration 49
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology 48
Squamous cell carcinoma of the penis: a case report 48
The presentation of a possible effect induced by human contact with a source of high voltage electrical current 48
Preoperative visualisation of Adamkiewicz artery by computed tomography in a patient with aortic aneurysm 48
Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 48
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 47
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion 45
Totale 9.620
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.008
article - articoli 16.144
book - libri 0
conference - conferenze 9.045
curatela - curatele 0
other - altro 2.819
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.016
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202253 0 0 0 0 11 5 0 4 3 3 6 21
2022/2023265 10 31 23 43 23 70 0 25 23 1 9 7
2023/2024192 7 6 10 18 26 29 12 17 11 17 28 11
2024/2025636 21 30 48 93 29 23 39 63 74 38 64 114
2025/20267.313 83 137 129 779 2.707 590 604 495 512 325 446 506
2026/20271.661 269 295 352 684 61 0 0 0 0 0 0 0
Totale 10.245